OOIR: Observatory of International Research

Papers

(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Letter: risk of severe COVID‐19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPARE‐IBD multicentre cohort study	141
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply	138
Letter: Ozanimod and latent tuberculosis	137
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	111
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply	102
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?	79
	71
Editorial: risk of pneumonia in IBD—reading between the lines!	70
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?	67
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	67
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	66
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	66
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	65
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	64
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	63
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	62
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	62
Letter: enhancing training opportunities for upper GI bleeding in Sheffield ‐ a UK transferable model? Authors' reply	58
Letter: faecal microbiota transplant in Clostridioides difficile infection: learning from the common water hyacinth	58
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	58
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	56
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected	55
Editorial: Plants against animals	55
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study	55
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	54

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply	53
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	52
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	52
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	48
AP&T: Editors' Declarations of Interest	48
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment	48
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	48
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	46
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply	46
	46
Issue Information	45
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	45
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	45
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	45
Editorial: Can we predict or not predict response to hypnotherapy? That is the question	44
Issue Information	43
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	42
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	42